For Patients and Caregivers

How to Order Single-Dose XOFLUZA Samples

Prepare now. Be ready for your first flu patient.

Sample a Full Course of Flu Treatment With Single-Dose XOFLUZA1

XOFLUZA® (baloxavir marboxil) Call Icon

Call 1-855-936-5892 to request a sample.

XOFLUZA® (baloxavir marboxil) Or Icon
XOFLUZA® (baloxavir marboxil) Or Icon
XOFLUZA® (baloxavir marboxil) Desktop Icon

On your desktop device, register or log in to the XOFLUZA Sampling Portal. Select a desired dose and electronically sign to request a sample.

What to expect with your XOFLUZA order

Your order will include:

  • One dose of either tablet of your choosing:
    • One 40-mg tablet for patients weighing ≥45 to <176 lb (≥20 kg to <80 kg)1
    • One 80-mg tablet for patients weighing ≥176 lb (≥80 kg)1
  • A pack of XOFLUZA coupons and a postcard highlighting affordability options to help your eligible patients save on XOFLUZA

Annual sample limits and other restrictions apply.

Drug samples may not be sold, purchased, traded, or offered for sale, purchase, or trade, utilized to seek reimbursement or otherwise distributed in a manner not permitted by applicable law. A sample may only be distributed to practitioners who are licensed or authorized under applicable state law to prescribe XOFLUZA and likely to treat patients consistent with its FDA-approved indication. Genentech reserves the right to deny fulfillment of XOFLUZA sample requests for any reason.

XOFLUZA® (baloxavir marboxil) Coupon Icon
Help Your Patients Save

Your eligible patients may pay as little as $35 (up to $70 off) for XOFLUZA.
Terms and conditions apply.

Download coupon

Frequently
asked
questions

You can direct your patients to the Savings Page of our website where they can learn about the XOFLUZA Coupon, allowing them to pay as little as $35, up to $70 off (Terms and conditions apply). They can also learn about our $50 self-pay option.

Coverage, patient out-of-pocket cost, copay programs, and sample availability can vary by plan, state, institution, and eligibility criteria.

The complete XOFLUZA prescribing information can be found here. It is also included with the dispensed drug.

You should consult the current FDA-approved US Prescribing Information for complete information on indications, limitations of use, dosing by weight and formulation, contraindications, warnings, adverse reactions, drug or food interactions, use in specific populations, and clinical study data.

Current CDC and local antimicrobial stewardship guidance should also be considered.

No. XOFLUZA is a prescription medication in the US and requires evaluation by a healthcare provider.1

Because XOFLUZA is indicated for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours, patients with suspected influenza (particularly those at high risk of influenza-related complications) should be evaluated promptly.1 Delayed presentation may place a patient outside the treatment window.

XOFLUZA is given as a single weight-based oral dose.1

The current U.S. Prescribing Information provides specific dose thresholds by body weight.1 You should confirm the exact tablet dose in the Prescribing Information.

IMPORTANT SAFETY INFORMATION & INDICATION

Indication

XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:

  • Treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications.
  • Post-exposure prophylaxis (PEP) of influenza in patients 5 years of age and older following contact with an individual who has influenza.

Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Important Safety Information

Contraindications
XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.

Warnings and Precautions

Hypersensitivity: Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.

Increased Incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-emergent resistance in this age group. In clinical trials, the incidence of virus with treatment-emergent substitutions associated with reduced susceptibility to baloxavir (resistance) was higher in pediatric subjects younger than 5 years of age (40%, 38/96) than in pediatric subjects ≥5 years to <12 years of age (16%, 19/117) or subjects ≥12 years of age (7%, 60/842). The potential for transmission of resistant strains in the community has not been determined.

Risk of bacterial infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Adverse Reactions

  • The most common adverse reactions (≥1%) in adult and adolescent patients (≥12 years of age) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).
  • The most frequently reported adverse reactions (≥5%) in pediatric patients (5 to <12 years of age) in clinical studies for acute uncomplicated influenza were vomiting (5%) and diarrhea (5%).
  • The safety profile reported in a clinical study for post-exposure prophylaxis was similar in pediatric patients ages 5 to <12 years old as that reported in adults and adolescents 12 years of age and older.

Drug Interactions
Polyvalent cations: Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, or zinc).

Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

For additional Important Safety Information, please see the XOFLUZA full Prescribing Information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

    • XOFLUZA. Prescribing information. Genentech, Inc.

      XOFLUZA. Prescribing information. Genentech, Inc.

    +